Douglas Morris - Bio Path Co-Founder and Director
| BPTHDelisted Stock | USD 0.19 0.01 5.00% |
Director
Mr. Douglas P. Morris is a Director of the Company. Mr. Morris is a cofounder of BioPath and has served as a director of BioPath since 2007 and served as an officer from 2007 to June 2014. Mr. Morris currently serves as Director of Investment Relations of BioPath. Mr. Morris previously served as a cofounder, Managing Member, and Secretary of nCAP Holdings, LLC, a privately held technology based company from September 2013 to January 2016. Between 1993 and 2010, Mr. Morris was an officer and director of Celtic Investment, Inc., a financial services company. Mr. Morris has owned and operated Hyacinth Resources, LLC, a businessconsulting firm since 1990 and is also a Managing Member of Sycamore Ventures, LLC, a privately held consulting firm since 2014.
| Age | 69 |
| Tenure | 11 years |
| Phone | 832 742 1357 |
| Web | https://www.biopathholdings.com |
Douglas Morris Latest Insider Activity
Tracking and analyzing the buying and selling activities of Douglas Morris against Bio Path otc stock is an integral part of due diligence when investing in Bio Path. Douglas Morris insider activity provides valuable insight into whether Bio Path is net buyers or sellers over its current business cycle. Note, Bio Path insiders must abide by specific rules, including filing SEC forms every time they buy or sell Bio Path'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Douglas Morris over a year ago Acquisition by Douglas Morris of 13000 shares of Bio Path subject to Rule 16b-3 |
Bio Path Management Efficiency
The company has return on total asset (ROA) of (1.9409) % which means that it has lost $1.9409 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.5974) %, meaning that it created substantial loss on money invested by shareholders. Bio Path's management efficiency ratios could be used to measure how well Bio Path manages its routine affairs as well as how well it operates its assets and liabilities.Bio Path Holdings currently holds 113 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Bio Path Holdings has a current ratio of 15.26, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Bio Path until it has trouble settling it off, either with new capital or with free cash flow. So, Bio Path's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bio Path Holdings sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bio to invest in growth at high rates of return. When we think about Bio Path's use of debt, we should always consider it together with cash and equity.
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas. Bio-Path Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. Bio Path Holdings [BPTH] is traded as part of a regulated electronic over-the-counter service offered by the NASD. Bio Path is listed under Pharmaceutical Products category by Fama And French industry classification. Management Performance
| Return On Equity | -11.6 | ||||
| Return On Asset | -1.94 |
Bio Path Holdings Leadership Team
Elected by the shareholders, the Bio Path's board of directors comprises two types of representatives: Bio Path inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bio. The board's role is to monitor Bio Path's management team and ensure that shareholders' interests are well served. Bio Path's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bio Path's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alan MacKenzie, Consultant | ||
| Thomas Walker, Consultant | ||
| MBA Ashizawa, Development Research | ||
| Michael MBA, VP Operations | ||
| Peter MBA, Chairman, CoFounder | ||
| Jeffery MD, Consultant | ||
| Victoria Rac, Regulatory Consultant | ||
| Anthony Price, Accounting Finance | ||
| Douglas Morris, Co-Founder and Director | ||
| MBA MBA, Development Research | ||
| Anthony MBA, Accounting Finance |
Bio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Bio Path a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -11.6 | ||||
| Return On Asset | -1.94 | ||||
| Current Valuation | 531.06 K | ||||
| Shares Outstanding | 5.77 M | ||||
| Shares Owned By Institutions | 7.41 % | ||||
| Number Of Shares Shorted | 79.35 K | ||||
| Price To Earning | (6.21) X | ||||
| Price To Book | 2.33 X | ||||
| EBITDA | (15.76 M) | ||||
| Net Income | (16.08 M) |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Bio OTC Stock
If you are still planning to invest in Bio Path Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bio Path's history and understand the potential risks before investing.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |